B
Bhagirathbhai Dholaria
Researcher at Vanderbilt University Medical Center
Publications - 135
Citations - 2003
Bhagirathbhai Dholaria is an academic researcher from Vanderbilt University Medical Center. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 12, co-authored 75 publications receiving 1032 citations. Previous affiliations of Bhagirathbhai Dholaria include University of Arkansas for Medical Sciences & Vanderbilt University.
Papers
More filters
Journal ArticleDOI
Next generation of immune checkpoint therapy in cancer: new developments and challenges
Julian A. Marin-Acevedo,Bhagirathbhai Dholaria,Aixa E. Soyano,Keith L. Knutson,Saranya Chumsri,Yanyan Lou +5 more
TL;DR: A comprehensive review of immune checkpoint pathways involved in cancer immunotherapy is provided, and their mechanisms and the therapeutic interventions currently under investigation in phase I/II clinical trials are discussed.
Journal ArticleDOI
Cancer immunotherapy beyond immune checkpoint inhibitors
TL;DR: This review is to include first-in-human phase I and phase I/II clinical trials intended to allow the identification of those drugs that most likely will continue to develop and possibly join the immunotherapeutic arsenal in a near future.
Journal ArticleDOI
Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma.
Jennifer M. Logue,Elisa Zucchetti,Christina A Bachmeier,Gabriel S Krivenko,Victoria Larson,Daniel Ninh,Giovanni Grillo,Biwei Cao,Jongphil Kim,Julio C. Chavez,Aliyah Baluch,Farhad Khimani,Aleksandr Lazaryan,Taiga Nishihori,Hien D. Liu,Javier Pinilla-Ibarz,Bijal D. Shah,Rawan Faramand,Anna E. Coghill,Marco L. Davila,Bhagirathbhai Dholaria,Michael D. Jain,Frederick L. Locke +22 more
TL;DR: Prolonged cytopenias are common following axi-cel therapy for LBCL and typically recover with time, but most patients experience profound and prolonged CD4 T-cell immunosuppression without severe infection.
Journal ArticleDOI
Peripheral blood biomarkers correlate with outcomes in advanced non-small cell lung Cancer patients treated with anti-PD-1 antibodies.
Aixa E. Soyano,Bhagirathbhai Dholaria,Julian A. Marin-Acevedo,Nancy N. Diehl,David O. Hodge,Yan Luo,Rami Manochakian,Saranya Chumsri,Alex A. Adjei,Keith L. Knutson,Yanyan Lou +10 more
TL;DR: Increased baseline ANC: ALC ratio and M: L ratio before initiation of anti-PD1 antibodies were associated with poor PFS and OS in advanced NSCLC patients, and their potential predictive value might help with risk stratification and treatment strategies.
Journal ArticleDOI
Emerging therapeutic agents for lung cancer
TL;DR: This review summarizes recent advances in lung cancer therapeutics with a specific focus on first in-human or early-phase I/II clinical trials for lung cancer, and divides the emerging agents into targeted agents, immunotherapies, and antibody drug conjugates for small cell lung cancer and non-small-cell lung cancer.